These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 13557081)

  • 21. Prevention of Rh-haemolytic disease.
    Clarke CA
    Br Med J; 1968 Jan; 1(5583):57-8. PubMed ID: 5636752
    [No Abstract]   [Full Text] [Related]  

  • 22. Rh prevention Manitoba 1969.
    Bowman JM
    Manit Med Rev; 1969; 49(7):14-6. PubMed ID: 5389752
    [No Abstract]   [Full Text] [Related]  

  • 23. Report on treatment of obstetric Rh isoimmunization with hapten.
    EHRENBERG CJ
    J Lancet; 1955 Jun; 75(6):275-7. PubMed ID: 14381742
    [No Abstract]   [Full Text] [Related]  

  • 24. [Management of Rh-negative pregnant women].
    LACOMBE V
    An Bras Ginecol; 1959 May; 47(5):257-64. PubMed ID: 13661605
    [No Abstract]   [Full Text] [Related]  

  • 25. Antepartum Rh immunoprophylaxis.
    N Engl J Med; 1981 Feb; 304(7):425-6. PubMed ID: 7453763
    [No Abstract]   [Full Text] [Related]  

  • 26. [The Medical Association: importance that Rh-prophylaxis begin as soon as possible].
    Lakartidningen; 1969 Jul; 66(29):2894. PubMed ID: 5804639
    [No Abstract]   [Full Text] [Related]  

  • 27. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in fetal nucleic acids in maternal plasma: implications to noninvasive prenatal fetal blood group genotyping.
    Lo YM
    Transfus Clin Biol; 2006; 13(1-2):50-2. PubMed ID: 16563836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Foetomaternal erythrocyte incompatibilities: from immunohaematologic surveillance of pregnant women to haemolytic disease of the newborn].
    Miquel E; Cavelier B; Bonneau JC; Rouger P
    Transfus Clin Biol; 2005 Feb; 12(1):45-55. PubMed ID: 15814293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical significance of anti-D IgG screening and titer detection in 286 RhD negative pregnant women].
    Liu KL; Li N; Li BJ; Peng JY; Shu XW; Yu YY
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Mar; 11(3):185-7. PubMed ID: 19292952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prevention of erythroblastosis fetalis by the use of Rh hapten.
    DIPPEL AL
    South Med J; 1952 Oct; 45(10):954-60. PubMed ID: 13005083
    [No Abstract]   [Full Text] [Related]  

  • 32. Noninvasive prenatal diagnosis of fetal Rhesus D: ready for Prime(r) Time.
    Bianchi DW; Avent ND; Costa JM; van der Schoot CE
    Obstet Gynecol; 2005 Oct; 106(4):841-4. PubMed ID: 16199645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible.
    Müller SP; Bartels I; Stein W; Emons G; Gutensohn K; Köhler M; Legler TJ
    Transfusion; 2008 Nov; 48(11):2292-301. PubMed ID: 18694461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunohematologic surveillance of the pregnant woman and the new prevention policy of anti-RH1 allo-immunization].
    Mannessier L
    Transfus Clin Biol; 2007 May; 14(1):112-9. PubMed ID: 17524695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prenatal care and delivery of the Rh negative patient.
    PRITCHARD JA
    J Ark Med Soc; 1959 Jun; 56(1):30-4. PubMed ID: 13664632
    [No Abstract]   [Full Text] [Related]  

  • 36. Is the recommended minimum dose of anti-D adequate considering the rise in obesity?
    Regan FA; Naftalin J; Springer V; Paterson-Brown S
    Transfus Med; 2008 Aug; 18(4):266-8. PubMed ID: 18783586
    [No Abstract]   [Full Text] [Related]  

  • 37. Should we continue screening rhesus D positive women for the development of atypical antibodies in late pregnancy?
    Adeniji AA; Fuller I; Dale T; Lindow SW
    J Matern Fetal Neonatal Med; 2007 Jan; 20(1):59-61. PubMed ID: 17437201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor-beta and prostaglandin E2.
    Branch DR; Shabani F; Lund N; Denomme GA
    Transfusion; 2006 Aug; 46(8):1316-22. PubMed ID: 16934066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Present-day management of the Rh-negative expectant mother and her erythroblastotic baby.
    WIENER AS
    Exp Med Surg; 1959; 17(1):15-30. PubMed ID: 13653065
    [No Abstract]   [Full Text] [Related]  

  • 40. The safety of RhIG in the prevention of haemolytic disease of the newborn.
    Hirose TG; Mays DA
    J Obstet Gynaecol; 2007 Aug; 27(6):545-57. PubMed ID: 17896248
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.